SCHEMBL14825534

SCHEMBL14825534

CCOC(=O)c1ccnc(CN2CCN(C(c3ccccc3)c3ccccc3F)CC2)c1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ OPRD1 P41143 6/20 0.49
▸ KCNH2 Q12809 4/20 0.49
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ ATM Q13315 3/20 0.45
▸ KDM4E B2RXH2 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ MAPK1 P28482 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ PRMT1 Q99873 1/20 0.40
▸ KDM5C P41229 2/20 0.40
▸ KDM4C Q9H3R0 2/20 0.40
▸ KDM5B Q9UGL1 2/20 0.40
▸ KDM5A P29375 1/20 0.40
▸ PIK3CA P42336 1/20 0.40
▸ POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14825504 0.94 OPRD1 (0.46) OPRD1KCNH2MEN1KMT2AATM
SCHEMBL14825403 0.91 OPRD1 (0.58) OPRD1KCNH2MEN1KMT2AATM
SCHEMBL14825424 0.89 OPRD1 (0.55) OPRD1KCNH2MEN1KMT2AATM
SCHEMBL14825535 0.88 KDM4C (0.53) OPRD1KCNH2MEN1KMT2AATM
SCHEMBL14825515 0.88 OPRD1 (0.51) OPRD1KCNH2MEN1KMT2AATM
SCHEMBL14825842 0.87 OPRD1 (0.54) OPRD1KCNH2MEN1KMT2AATM
SCHEMBL14825838 0.85 OPRD1 (0.55) OPRD1KCNH2MEN1KMT2AMAPK1
SCHEMBL14825362 0.85 OPRD1 (0.48) OPRD1KCNH2MEN1KMT2AATM
SCHEMBL14825488 0.84 OPRD1 (0.46) OPRD1KCNH2MEN1KMT2AATM
SCHEMBL14825474 0.84 CACNA2D1 (0.52) OPRD1KCNH2MEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
EP-2578569-B1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARM CO LTD (JP) 2015-10-28 — — EP disclosed
EP-2578569-A1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA Pharmaceutical Co., Ltd. (JP) 2013-04-10 — — EP disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST HRH2, HRH4, HRH1 OPRD1 129/4885KCNH2 308/4885MEN1 2318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback